Patents by Inventor Gavin C. Hirst
Gavin C. Hirst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11897900Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.Type: GrantFiled: December 18, 2020Date of Patent: February 13, 2024Assignee: Janssen Pharmaceutica NVInventors: J. Kent Barbay, Wenying Chai, Gavin C. Hirst, Kevin D. Kreutter, David A. Kummer, Kelly J. McClure, Rachel T. Nishimura, Amy Y. Shih, Jennifer D. Venable, Hariharan Venkatesan, Jianmei Wei
-
Publication number: 20230150985Abstract: Chromanone compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the inhibition of antigen presentation by HLA-DR.Type: ApplicationFiled: March 30, 2021Publication date: May 18, 2023Inventors: Joseph Kent Barbay, Stephane Becart, Kelly L. Damm-Ganamet, Gavin C. Hirst, Kevin D. Kreutter, Alec D. Lebsack
-
Publication number: 20220315604Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.Type: ApplicationFiled: December 18, 2020Publication date: October 6, 2022Inventors: J. Kent Barbay, Wenying Chai, Gavin C. Hirst, Kevin D. Kreutter, David A. Kummer, Kelly J. McClure, Rachel T. Nishimura, Amy Y. Shih, Jennifer D. Venable, Hariharan Venkatesan, Jianmei Wei
-
Patent number: 11427601Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.Type: GrantFiled: August 30, 2021Date of Patent: August 30, 2022Assignee: Janssen Pharmaceutica NVInventors: J. Kent Barbay, Wenying Chai, Gavin C. Hirst, Kevin D. Kreutter, David A. Kummer, Kelly J. McClure, Rachel T. Nishimura, Amy Y. Shih, Jennifer D. Venable, Hariharan Venkatesan, Jianmei Wei
-
Patent number: 10947252Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.Type: GrantFiled: August 19, 2019Date of Patent: March 16, 2021Assignee: Janssen Pharmaceutica NVInventors: J. Kent Barbay, Wenying Chai, Gavin C. Hirst, Kevin D. Kreutter, David A. Kummer, Kelly J. McClure, Rachel T. Nishimura, Amy Y. Shih, Jennifer D. Venable, Hariharan Venkatesan, Jianmei Wei
-
Publication number: 20200055874Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.Type: ApplicationFiled: August 19, 2019Publication date: February 20, 2020Inventors: J. Kent Barbay, Wenying Chai, Gavin C. Hirst, Kevin D. Kreutter, David A. Kummer, Kelly J. McClure, Rachel T. Nishimura, Amy Y. Shih, Jennifer D. Venable, Hariharan Venkatesan, Jianmei Wei
-
Patent number: 8273736Abstract: Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.Type: GrantFiled: November 20, 2009Date of Patent: September 25, 2012Assignee: Abbott LaboratoriesInventors: Patrick Betschmann, Andrew F. Burchat, David J. Calderwood, Michael L. Curtin, Steven K. Davidsen, Heather M. Davis, Robin R. Frey, Howard R. Heyman, Gavin C. Hirst, Peter Hrnciar, Michael R. Michaelides, Melanie A. Muckey, Kelly D. Mullen, Paul Rafferty, Carol K. Wada
-
Patent number: 7863444Abstract: Chemical compounds having structural formula I and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disase states where angiogenesis or endothelial cell hyperproliferaton is a factor. These compounds can be used to treat cancer, hyperproliferative disorders, rheumatoid artheritis, disorders of the immune system, transplant rejection, and inflammatory disorders.Type: GrantFiled: September 17, 1999Date of Patent: January 4, 2011Assignee: Abbott LaboratoriesInventors: David Calderwood, Lee Arnold, Hormoz Mazdiyasni, Gavin C. Hirst, Bojuan B. Deng, David N. Johnston, Paul Rafferty, Gerald B. Tometzki, Helen L. Twigger, Rainer Munschauer
-
Patent number: 7829570Abstract: The present application is directed to compounds of the formula (I) wherein the substituents are as defined herein, which are useful as kinase inhibitors.Type: GrantFiled: December 3, 2008Date of Patent: November 9, 2010Assignee: Abbott LaboratoriesInventors: Gavin C. Hirst, Andrew Burchat, Neil Wishart, David J. Calderwood, Michael R. Michaelides, Zhiqin Ji
-
Patent number: 7737160Abstract: Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.Type: GrantFiled: February 15, 2007Date of Patent: June 15, 2010Assignee: Abbott Laboratories Inc.Inventors: Patrick Betschmann, Andrew F. Burchat, David J. Calderwood, Michael L. Curtin, Steven K. Davidsen, Heather M. Davis, Robin R. Frey, Howard R. Heyman, Gavin C. Hirst, Peter Hrnciar, Michael R. Michaelides, Melanie A. Muckey, Kelly D. Mullen, Paul Rafferty, Carol K. Wada
-
Patent number: 7709468Abstract: The present invention is directed to novel imidazopyrazine and imidazopyrimidine compounds of formula (I) wherein the variables are as defined herein. The compounds of formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.Type: GrantFiled: September 1, 2006Date of Patent: May 4, 2010Assignee: Abbott LaboratoriesInventors: David J. Calderwood, Kristine E. Frank, Patrick Betschmann, Gavin C. Hirst, Eric C. Brieinlinger, Michael J. Morytko, Richard W. Dixon
-
Publication number: 20100069371Abstract: Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.Type: ApplicationFiled: November 20, 2009Publication date: March 18, 2010Applicant: ABBOTT LABORATORIESInventors: Patrick Betschmann, Andrew F. Burchat, David J. Calderwood, Michael L. Curtin, Steven K. Davidsen, Heather M. Davis, Robin R. Frey, Howard R. Heyman, Gavin C. Hirst, Peter Hrnciar, Michael R. Michaelides, Melanie A. Muckey, Kelly D. Mullen, Paul Rafferty, Carol K. Wada
-
Publication number: 20100041676Abstract: The present application is directed to compounds of the formula (I) wherein the substituents are as defined herein, which are useful as kinase inhibitors.Type: ApplicationFiled: December 3, 2008Publication date: February 18, 2010Inventors: Gavin C. Hirst, Andrew Burchat, Neil Wishart, David J. Calderwood, Michael R. Michaelides, Zhiqin Ji
-
Patent number: 7400979Abstract: The present invention relates to polypeptides which comprise the ligand binding domain of Lck, crystalline forms of these polypeptides, and the use of these crystalline forms to determine the three dimensional structure of the catalytic domain of Lck. The invention also relates to the use of the three dimensional structure of the Lck catalytic domain both alone, or in complex with inhibitors, in methods of designing and/or identifying potential inhibitors of Lck activity, for example, compounds which inhibit the binding of a native substrate to the Lck catalytic domain. The invention also relates to the use of the three dimensional structure of the Lck catalytic domain both alone, or in complex with inhibitors, in methods of designing and/or identifying potential selective inhibitors of Lck activity, for example, compounds which inhibit the binding of a native substrate to the Lck catalytic domain selectively.Type: GrantFiled: August 5, 2002Date of Patent: July 15, 2008Assignee: Abbott LaboratoriesInventors: David W. Borhani, David Calderwood, Richard W. Dixon, Gavin C. Hirst, Peter Hrnciar, Andreas Loew, Adelaine Leung, Kurt Ritter
-
Patent number: 7332497Abstract: The present invention provides compounds of Formula I, including pharmaceutically acceptable salts and/or prodrugs thereof, where G, Ra, R2, and R3 are defined as described herein.Type: GrantFiled: March 22, 2002Date of Patent: February 19, 2008Assignee: Abbott GmbH & Co KGInventors: Gavin C. Hirst, Paul Rafferty, Kurt Ritter, David Calderwood, Neil Wishart, Lee D. Arnold, Michael M. Friedman
-
Patent number: 7202363Abstract: Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.Type: GrantFiled: July 26, 2004Date of Patent: April 10, 2007Assignee: Abbott LaboratoriesInventors: Patrick Betschmann, Andrew F. Burchat, David J. Calderwood, Michael L. Curtin, Steven K. Davidsen, Heather M. Davis, Robin R. Frey, Howard R. Heyman, Gavin C. Hirst, Peter Hrnciar, Michael R. Michaelides, Melanie A. Muckey, Kelly D. Mullen, Paul Rafferty, Carol K. Wada
-
Patent number: 7071199Abstract: The present application is directed to a compound of Formula (I) as defined herein which are useful as kinase inhibitors.Type: GrantFiled: September 15, 2000Date of Patent: July 4, 2006Assignee: Abbott GmbH & CCo. KGInventors: Gavin C. Hirst, Paul Rafferty, Kurt Ritter, David Calderwood, Helen Twigger, Stephen St. Gallay
-
Patent number: 6921763Abstract: The present invention is directed to pyrazolopyrimidine derivatives of formula (I) wherein the substituents are defined herein, which are useful as kinase inhibitors and as such are useful for affecting angiogenesis and diseases and conditions associated with angiogenesis.Type: GrantFiled: March 22, 2001Date of Patent: July 26, 2005Assignee: Abbott LaboratoriesInventors: Gavin C. Hirst, Paul Rafferty, Kurt Ritter, David Calderwood, Neil Wishart, Lee D. Arnold, Michael M. Friedman
-
Patent number: 6713474Abstract: Chemical compounds having structural formula I and physiologically acceptable salts and metabolites thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases, whose activity is inhibited by these chemical compounds, are involved in immunologic, hyperproliferative, or angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyper proliferative disorders, rheumatiod arthritis, disorders of the immune system, trasplant rejections and imflammatory disorders.Type: GrantFiled: March 29, 2000Date of Patent: March 30, 2004Assignee: Abbott GmbH & Co. KGInventors: Gavin C. Hirst, David Calderwood, Rainer Munschauer, Lee D. Arnold, David N. Johnston, Paul Rafferty
-
Publication number: 20040006083Abstract: The present invention provides compounds of Formula I, 1Type: ApplicationFiled: July 19, 2002Publication date: January 8, 2004Inventors: Gavin C. Hirst, Paul Rafferty, Kurt Ritter, David Calderwood, Neil Wishart, Lee D. Arnold, Michael M. Friedman